Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Trastuzumab
Related studies linked through entity extraction aliases.
Lapatinib and Trastuzumab With or Without Endocrine Therapy
- Status
- COMPLETED
- Phase
- PHASE2
Bevacizumab in Multiple Phase I Combinations
- Status
- COMPLETED
- Phase
- PHASE1
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Trastuzumab or Observation After Combination Chemotherapy and Trastuzumab in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.
- Status
- COMPLETED
- Phase
- PHASE2
Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
- Status
- TERMINATED
- Phase
- PHASE3
Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE3
A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
- Status
- COMPLETED
- Phase
- PHASE3
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE3
Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE2
Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
- Status
- COMPLETED
- Phase
- PHASE3
Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
- Status
- COMPLETED
- Phase
- PHASE2